Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Latest From Ashley Yeo
The UK has added important new capabilities to its COVID-19 monitoring and control effort and those running it promise a “world class system” by late summer.
The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.
The advent of COVID-19 and its effects on care delivery have meant that short-term priorities for health care systems have switched temporarily to public health emergency mode. But the longer-term need to restructure delivery around outcomes and federated data management for patients is here to stay, says Royal Philips’ Jeroen Tas.
Philips has added a Clinical Trials Accelerator functionality to the cloud-based HealthSuite digital platform, underlining its role in securely managing and collecting device and personal data for use by third-party clients seeking to build health care solutions.
South Korea, one of the first countries to be hit by the spread of COVID-19 from China, has implemented new standalone IVD regulations.
Post-Brexit planning is now fully back on the agenda in the UK, and work to shape its post-EU medtech regulatory future is also restarting.